2830-53-7

Usage

Uses

Used in Pharmaceutical Industry:
1-(Benzyloxy)-2-bromo-4-methylbenzene is used as a building block for the preparation of various pharmaceuticals. Its unique structure allows it to be a key component in the synthesis of new drugs, contributing to the development of innovative treatments.
Used in Agrochemicals:
In the agrochemical industry, 1-(Benzyloxy)-2-bromo-4-methylbenzene is utilized as a precursor for the synthesis of various agrochemicals. Its properties make it suitable for the development of new pesticides and other agricultural chemicals to improve crop protection and yield.
Used in Specialty Chemicals Production:
1-(Benzyloxy)-2-bromo-4-methylbenzene is employed as a building block in the production of specialty chemicals. Its unique structure and reactivity enable the creation of customized chemical products for specific applications in various industries.
Used in Dyes and Fine Chemicals:
1-(BENZYLOXY)-2-BROMO-4-METHYLBENZENE is also used in the production of dyes and other fine chemicals. Its chemical properties make it a valuable component in the synthesis of high-quality dyes for various applications, including textiles, plastics, and printing inks.
Used in Academic Research:
1-(Benzyloxy)-2-bromo-4-methylbenzene serves as a reagent in academic research for various chemical reactions. Its unique structure and reactivity make it a valuable tool for chemists to explore new reaction pathways and develop novel synthetic methods.
It is important to handle 1-(Benzyloxy)-2-bromo-4-methylbenzene with care, as it may be hazardous if mishandled. Proper safety measures should be taken during its use to ensure the safety of researchers and the environment.

InChI:InChI=1/C14H13BrO/c1-11-7-8-14(13(15)9-11)16-10-12-5-3-2-4-6-12/h2-9H,10H2,1H3

Upstream product

• 6627-55-0 2-bromo-p-cresol 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 22002-45-5 2-bromo-4-methylanisole 

Downstream Products

• 19803-00-0 4-Benzyloxy-3-(4-methyl-phenoxy)-toluol 
• 69455-11-4 2-(2-Benzyloxy-5-methyl-phenyl)-cyclohepta-2,4,6-trienone 
• 215929-27-4 (R)-3-[(R)-3-(2-benzyloxy-5-methylphenyl)-3-phenylpropionyl]-4-phenyloxazolidin-2-one 
• 220223-05-2 2-benzyloxy-5-methylbenzenesulfonyl chloride 
• 109588-48-9 2-methyl-6H-benzo[c]benzopyran 
• 834-25-3 4-methylphenyl benzyl ether 
• 58110-77-3 3,5-dimethyl-2-phenylbenzo[b]furan 
• 53389-98-3 2-(benzyloxy)-5-methylsalicylaldehyde 
• 180211-49-8 2-(2-benzyloxy-5-methylphenyl)-1-methylcyclopent-2-ene-1-carboxylic acid 
• 180211-48-7 2-(2-Benzyloxy-5-methyl-phenyl)-1-methyl-cyclopent-2-enecarboxylic acid ethyl ester 
• 396-44-1 3,3’,5,5’-tetrakis(trifluoromethyl)biphenyl 
• 1238894-71-7 (S)-4-methyl-2-(2-hydroxypropyl)phenol 
• 1238894-60-4 (R)-(-)-1-[2-(benzyloxy)-5-methylphenyl]propan-2-yl acetate 
• 1238894-64-8 (S)-(+)-1-[2-(benzyloxy)-5-methylphenyl]propan-2-ol 

Relevant academic research and scientific papers

Facile and divergent optimization of chromazonarol enabled the identification of simplified drimane meroterpenoids as novel pharmaceutical leads

The diversity of drimane hydroquinones was significantly expanded by the facile construction of (+)-chromazonarol relevant natural products, isomers, and analogues for the discovery of new pharmaceutical leads. The structure-activity relationship of (+)-c

BENZOFURAN PYRAZOLE AMINE PROTEIN KINASE INHIBITOR

The present invention discloses a compound for regulating protein kinase activity and used for treating or preventing diseases associated with protein kinases. Specifically, the present invention relates to a benzofuran pyrazole amine protein kinase inhib

BRIDGED BIPHENYL PHENOL TRANSITION METAL COMPLEXES, PRODUCTION, AND USE THEREOF

The present disclosure provides catalysts having a homoallylic bridge (and/or naphthyl moieties) located at a certain position on the catalysts which provides catalyst productivity values of 10,000 gPgcat-1hr-1 or greater and polyole

CERTAIN PROTEIN KINASE INHIBITORS

Disclosed herein are protein kinase inhibitors, more particu-larly novel pyrimidine derivatives and pharmaceutical com-positions thereof, and method of use thereof

Straightforward synthesis of enantiopure 2,3-dihydrobenzofurans by a sequential stereoselective biotransformation and chemical intramolecular cyclization

(Equation Presented). A new family of optically active 2,3- dihydrobenzofurans has been prepared by a simple chemoenzymatic asymmetric strategy. This synthetic approach is based on the combination of a lipase-mediated kinetic resolution of 1-aryl-2-propanols or bioreduction of the corresponding ketones followed by an intramolecular cyclization reaction. These novel compounds have been prepared in enantiopure form and in good overall yield through a straightforward route.

2,4-Bis(fluorocarbon)-substituted phenols for high yield Newman-Kwart rearrangement reactions

The Newman-Kwart thermal rearrangement of two 2,4-disubstituted O-arylthiocarbamates, prepared from the corresponding phenols, is reported. Clean conversion to the S-arylthiocarbamates in high yields was observed. The rearrangement appears to be facilitat

DERIVATIVES OF 3-(2-HYDROXY-5-METHYPHENYL)-N,N-DIISOPROPYL-3-PHENYLPROPYLAMINE AND METHODS OF USE THEREOF

This invention relates to novel derivatives of tolterodine, 5-hydroxymethyl tolterodine, fesoterodine and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such comp

Rhodium/chiral diene-catalyzed asymmetric 1,4-addition of arylboronic acids to arylmethylene cyanoacetates

Asymmetric 1,4-addition of arylboronic acids to (￡)-methyl 2-cyano-3-arylpropenoates proceeded in the presence of a rhodium catalyst (3 mol %) coordinated with a chiral diene ligand, (R,R)-Ph-bod*, to give high yields of the corresponding methyl 3,3-diaryl-2-cyanopropanoates with high enantioselectivity (up to 99% ee). This catalytic asymmetric transformation was applied to the asymmetric synthesis of (R)-tolterodine. American Chemical Society.

NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES

A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is -O-, -CH2-, or -NH-; n is an integer selected between 0 and 1; R6 and R7 each independently is hydrogen or C1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q1 to Q5; Ar1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.